Liver cancer begins in the cells of the liver. The most common form of liver cancer begins in cells called hepatocytes and is called hepatocellular carcinoma (HCC).
The risk of hepatocellular carcinoma, is higher in people with long-term liver diseases. It's also higher if the liver is scarred by infection with hepatitis B or hepatitis C. Hepatocellular carcinoma is more common in people who drink large amounts of alcohol and who have an accumulation of fat in the liver.
Contact
Name: Wei Wang, MD
Phone: 86-0731-88618411
Email: cjr.wangwei@vip.163.com
Name: Xiaoqian Ma, MD
Phone: 86-0731-88618413
Email: 85316745@qq.com
China, Hunan
The 3rd Xiangya Hospital of Central South University, Changsha, Hunan, China, 410013
Status: Active recruiting
Description
This is a clinical study to investigate the safety and effect of transcatheter arterial chemoembolization (TACE) in combination with PD-1 knockout engineered T cells in the Patients with advanced hepatocellular carcinoma. TACE would block the blood supply of the tumor to achieve ischemic, hypoxic and necrotic effects. The PD-1 knockout engineered T cells were also prepared from autologous origin using CRISPR Cas9 technology. The patients performed one TACE treatment followed by 3 cycles of PD-1 edited T cells by percutaneous infusion in the peripheral of tumor under the guide of CT every four weeks. The safety and clinical efficacy will be evaluated. Biomarkers and immunological markers will be monitored.
Last updated: Dec. 12, 2024